Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | EYA2 | O00167 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860473 | 1.00 | LMNA (0.36) | LMNABLMMEN1HBBKMT2A | |
| SCHEMBL14066120 | 1.00 | LMNA (0.36) | LMNABLMMEN1HBBKMT2A | |
| SCHEMBL4860492 | 1.00 | LMNA (0.36) | LMNABLMMEN1HBBKMT2A | |
| SCHEMBL7596531 | 0.98 | LMNA (0.34) | LMNABLMMEN1HBBKMT2A | |
| SCHEMBL6013898 | 0.76 | CYP3A4 (0.35) | LMNAALOX15CYP3A4 | |
| SCHEMBL29956579 | 0.75 | — | — | |
| SCHEMBL15405222 | 0.70 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL15405225 | 0.70 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL15422932 | 0.65 | — | — | |
| SCHEMBL21778 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425218-B2 | Nitric oxide-releasing medical devices | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1666047-A1 | Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones | The Government of the United States of America As represented by the Secretary of the Department Of Health and Human Services (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0793500-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING POLYSACCHARIDES | US GOV HEALTH & HUMAN SERV (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20020119115-A1 | Nitric oxide-releasing medical devices | OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH (US) | 2002-08-29 | — | — | US | disclosed |
| US-6379660-B1 | BIOPOLYMERS; ADMINISTERING THERAPY DOSAGE; ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-30 | — | — | US | disclosed |
| US-6200558-B1 | PEPTIDE, POLYPEPTIDE, PROTEIN, OLIGONUCLEOTIDE OR NUCLEIC ACID, TO WHICH IS BOUND A NITRIC OXIDE-RELEASING N2O2-FUNCTIONAL GROUP | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-03-13 | — | — | US | disclosed |
| US-5700830-A | Use of nitric oxide-releasing agents for reducing metastasis risk | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-23 | — | — | US | disclosed |
| US-5632981-A | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119115-A1 | Nitric oxide-releasing medical devices | NOS2, NOS1, NOS3 | LMNA 3236/4885BLM 1919/4885MEN1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.